Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1110

2.
3.

Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.

Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.

Am J Manag Care. 2002 Oct;8(15 Suppl):S414-27.

4.

What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.

Hochberg MC.

Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S15-22. Review.

PMID:
11695246
6.
7.

Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients.

Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM; SUCCESS VI Study Group..

Am J Ther. 2001 Mar-Apr;8(2):85-95. Erratum in: Am J Ther 2001 May-Jun;8(3):220.

PMID:
11304662
8.

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.

Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J.

Circulation. 2004 May 4;109(17):2068-73.

9.

Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors.

Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.

Am J Manag Care. 2002 Oct;8(15 Suppl):S401-13.

10.

Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.

Zhao SZ, Wentworth C, Burke TA, Makuch RW.

Pharmacoepidemiol Drug Saf. 2004 May;13(5):277-87.

PMID:
15133778
12.

The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.

Spiegel BM, Targownik L, Dulai GS, Gralnek IM.

Ann Intern Med. 2003 May 20;138(10):795-806. Review.

PMID:
12755551
14.

Factors associated with celecoxib and rofecoxib utilization.

Rawson NS, Nourjah P, Grosser SC, Graham DJ.

Ann Pharmacother. 2005 Apr;39(4):597-602.

PMID:
15755796
15.
16.

An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis.

Schnitzer TJ, Kong SX, Mitchell JH, Mavros P, Watson DJ, Pellissier JM, Straus WL.

Clin Ther. 2003 Dec;25(12):3162-72.

PMID:
14749154
17.
18.

The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.

Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG; Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators..

Arch Intern Med. 2005 Jan 24;165(2):161-8. Erratum in: Arch Intern Med. 2005 Mar 14;165(5):551.

PMID:
15668361
Items per page

Supplemental Content

Support Center